Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Penile Neoplasms | 33 | 2020 | 162 | 4.360 |
Why?
|
Carcinoma, Squamous Cell | 33 | 2020 | 4024 | 1.600 |
Why?
|
Carcinoma in Situ | 9 | 2020 | 796 | 0.880 |
Why?
|
Penis | 6 | 2011 | 212 | 0.750 |
Why?
|
Precancerous Conditions | 11 | 2020 | 977 | 0.560 |
Why?
|
Lichen Sclerosus et Atrophicus | 5 | 2020 | 28 | 0.540 |
Why?
|
Papillomavirus Infections | 9 | 2019 | 1607 | 0.470 |
Why?
|
Condylomata Acuminata | 5 | 2019 | 75 | 0.460 |
Why?
|
Anti-Inflammatory Agents | 2 | 2011 | 1796 | 0.370 |
Why?
|
Skin Neoplasms | 8 | 2018 | 5799 | 0.370 |
Why?
|
Micrococcaceae | 1 | 2010 | 8 | 0.360 |
Why?
|
Melanoma | 10 | 2018 | 5697 | 0.340 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2008 | 49 | 0.320 |
Why?
|
Papillomaviridae | 4 | 2019 | 1117 | 0.320 |
Why?
|
Trypanocidal Agents | 3 | 2015 | 41 | 0.320 |
Why?
|
Aluminum | 1 | 2008 | 152 | 0.300 |
Why?
|
Dermatitis | 1 | 2010 | 200 | 0.300 |
Why?
|
Pathology, Clinical | 2 | 2020 | 375 | 0.300 |
Why?
|
Nitroimidazoles | 3 | 2015 | 117 | 0.290 |
Why?
|
Trypanosoma cruzi | 4 | 2015 | 206 | 0.270 |
Why?
|
Alopecia | 1 | 2011 | 414 | 0.270 |
Why?
|
Granuloma | 1 | 2008 | 327 | 0.270 |
Why?
|
Antibodies, Monoclonal | 6 | 2014 | 9185 | 0.270 |
Why?
|
Cicatrix | 2 | 2010 | 782 | 0.260 |
Why?
|
Urethral Neoplasms | 1 | 2005 | 37 | 0.250 |
Why?
|
Chagas Disease | 3 | 2013 | 167 | 0.250 |
Why?
|
Peripheral Nerves | 1 | 2008 | 475 | 0.240 |
Why?
|
Tumor Virus Infections | 1 | 2007 | 438 | 0.240 |
Why?
|
Clinical Protocols | 1 | 2010 | 1440 | 0.230 |
Why?
|
Neprilysin | 1 | 2007 | 472 | 0.230 |
Why?
|
Phimosis | 1 | 2003 | 10 | 0.220 |
Why?
|
Urethra | 1 | 2005 | 406 | 0.210 |
Why?
|
Bacteremia | 1 | 2010 | 980 | 0.210 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2016 | 217 | 0.210 |
Why?
|
Carcinoma, Basosquamous | 2 | 2012 | 7 | 0.210 |
Why?
|
Skin | 4 | 2010 | 4466 | 0.210 |
Why?
|
Papillomavirus Vaccines | 1 | 2008 | 495 | 0.200 |
Why?
|
Psoriasis | 1 | 2010 | 940 | 0.200 |
Why?
|
Endemic Diseases | 2 | 2012 | 190 | 0.180 |
Why?
|
Antigens, Neoplasm | 2 | 2011 | 1998 | 0.180 |
Why?
|
Balanitis Xerotica Obliterans | 1 | 2020 | 2 | 0.180 |
Why?
|
Lymphatic Metastasis | 6 | 2017 | 2943 | 0.170 |
Why?
|
Skin Diseases | 1 | 2008 | 1089 | 0.170 |
Why?
|
Urogenital Neoplasms | 1 | 2021 | 135 | 0.170 |
Why?
|
Lymph Nodes | 3 | 2010 | 3486 | 0.160 |
Why?
|
Neoplasm Invasiveness | 5 | 2010 | 3618 | 0.160 |
Why?
|
Chagas Cardiomyopathy | 2 | 2015 | 71 | 0.150 |
Why?
|
Biopsy | 4 | 2010 | 6771 | 0.140 |
Why?
|
Immunohistochemistry | 8 | 2020 | 11070 | 0.140 |
Why?
|
Carcinoma, Verrucous | 2 | 2010 | 27 | 0.130 |
Why?
|
Male | 47 | 2021 | 359718 | 0.130 |
Why?
|
Nevus, Pigmented | 1 | 2018 | 221 | 0.130 |
Why?
|
Aged, 80 and over | 20 | 2020 | 58980 | 0.130 |
Why?
|
Carcinoma, Papillary | 2 | 2012 | 785 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2010 | 9278 | 0.130 |
Why?
|
Paraguay | 3 | 2011 | 7 | 0.120 |
Why?
|
Penile Diseases | 1 | 2014 | 45 | 0.120 |
Why?
|
Neoplasm Staging | 4 | 2017 | 11152 | 0.120 |
Why?
|
Middle Aged | 33 | 2020 | 220359 | 0.110 |
Why?
|
Terminology as Topic | 2 | 2012 | 1535 | 0.110 |
Why?
|
Humans | 61 | 2021 | 760613 | 0.110 |
Why?
|
Nifurtimox | 1 | 2013 | 14 | 0.110 |
Why?
|
Neoplasm Metastasis | 3 | 2010 | 4902 | 0.110 |
Why?
|
Diagnosis, Differential | 7 | 2012 | 12968 | 0.110 |
Why?
|
Parakeratosis | 1 | 2012 | 2 | 0.100 |
Why?
|
Antibodies, Protozoan | 2 | 2013 | 251 | 0.100 |
Why?
|
Foreskin | 1 | 2011 | 31 | 0.100 |
Why?
|
Aged | 26 | 2020 | 169143 | 0.100 |
Why?
|
Polymerase Chain Reaction | 6 | 2019 | 6065 | 0.100 |
Why?
|
Nevus | 1 | 2013 | 205 | 0.090 |
Why?
|
Neoplasms, Basal Cell | 1 | 2011 | 31 | 0.090 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2011 | 197 | 0.090 |
Why?
|
Actinomycetales Infections | 1 | 2010 | 30 | 0.090 |
Why?
|
Membrane Proteins | 1 | 2007 | 7850 | 0.090 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2011 | 698 | 0.090 |
Why?
|
Merkel Cells | 1 | 2009 | 24 | 0.090 |
Why?
|
Behcet Syndrome | 1 | 2010 | 86 | 0.080 |
Why?
|
Acantholysis | 1 | 2009 | 11 | 0.080 |
Why?
|
Cysts | 1 | 2014 | 683 | 0.080 |
Why?
|
Pregnancy Complications, Parasitic | 1 | 2009 | 61 | 0.080 |
Why?
|
Adult | 23 | 2020 | 220007 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2011 | 4356 | 0.080 |
Why?
|
Melanocytes | 2 | 2009 | 512 | 0.080 |
Why?
|
Hyperplasia | 3 | 2011 | 1155 | 0.080 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 9406 | 0.080 |
Why?
|
Prognosis | 8 | 2012 | 29661 | 0.080 |
Why?
|
SOXB1 Transcription Factors | 1 | 2009 | 286 | 0.080 |
Why?
|
Keratinocytes | 1 | 2012 | 792 | 0.080 |
Why?
|
Crohn Disease | 2 | 2011 | 2275 | 0.080 |
Why?
|
Melanoma, Amelanotic | 1 | 2007 | 19 | 0.070 |
Why?
|
Point Mutation | 1 | 2013 | 1594 | 0.070 |
Why?
|
In Situ Hybridization | 2 | 2016 | 1900 | 0.070 |
Why?
|
Cytoplasm | 1 | 2012 | 1516 | 0.070 |
Why?
|
Pathology, Molecular | 2 | 2021 | 329 | 0.070 |
Why?
|
Opportunistic Infections | 1 | 2010 | 377 | 0.070 |
Why?
|
Plasma Cells | 1 | 2010 | 591 | 0.070 |
Why?
|
Drug Therapy | 1 | 2010 | 504 | 0.070 |
Why?
|
Lipodystrophy | 1 | 2007 | 148 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3802 | 0.060 |
Why?
|
Head and Neck Neoplasms | 2 | 2010 | 2882 | 0.060 |
Why?
|
Eosinophils | 1 | 2010 | 944 | 0.060 |
Why?
|
Autopsy | 1 | 2009 | 1007 | 0.060 |
Why?
|
Young Adult | 9 | 2020 | 58748 | 0.060 |
Why?
|
Circumcision, Male | 2 | 2004 | 148 | 0.060 |
Why?
|
Keratosis | 1 | 2005 | 80 | 0.060 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 1728 | 0.060 |
Why?
|
Genes, Neoplasm | 1 | 2007 | 370 | 0.060 |
Why?
|
Immunocompromised Host | 1 | 2010 | 857 | 0.060 |
Why?
|
Scalp | 1 | 2007 | 389 | 0.060 |
Why?
|
Metaplasia | 1 | 2005 | 320 | 0.060 |
Why?
|
Immunologic Memory | 1 | 2011 | 1354 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-kit | 1 | 2008 | 727 | 0.060 |
Why?
|
Survival Analysis | 2 | 2007 | 10185 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2007 | 597 | 0.060 |
Why?
|
Societies, Medical | 2 | 2020 | 3905 | 0.060 |
Why?
|
Genotype | 5 | 2019 | 12957 | 0.060 |
Why?
|
Epithelium | 2 | 2005 | 1605 | 0.060 |
Why?
|
Reproducibility of Results | 3 | 2018 | 20080 | 0.060 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2007 | 586 | 0.050 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2005 | 413 | 0.050 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2007 | 487 | 0.050 |
Why?
|
Antigens, CD | 2 | 2011 | 4000 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2896 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2011 | 4550 | 0.050 |
Why?
|
Consensus | 1 | 2010 | 3113 | 0.040 |
Why?
|
Argentina | 2 | 2012 | 245 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7475 | 0.040 |
Why?
|
Female | 18 | 2015 | 391246 | 0.040 |
Why?
|
Down-Regulation | 1 | 2007 | 2913 | 0.040 |
Why?
|
Risk Factors | 3 | 2017 | 74333 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 3612 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2008 | 1152 | 0.040 |
Why?
|
World Health Organization | 2 | 2018 | 1314 | 0.040 |
Why?
|
Valine | 1 | 2000 | 409 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1408 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11345 | 0.040 |
Why?
|
Piperazines | 1 | 2008 | 2525 | 0.040 |
Why?
|
Skin Aging | 1 | 1998 | 141 | 0.030 |
Why?
|
Adolescent | 8 | 2020 | 87809 | 0.030 |
Why?
|
United States | 2 | 2017 | 72448 | 0.030 |
Why?
|
Pyrimidines | 1 | 2008 | 3016 | 0.030 |
Why?
|
Human papillomavirus 18 | 1 | 2016 | 125 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2010 | 15286 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2802 | 0.030 |
Why?
|
Urology | 1 | 2020 | 423 | 0.030 |
Why?
|
Recurrence | 1 | 2007 | 8483 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2010 | 3763 | 0.030 |
Why?
|
Epitopes | 2 | 2011 | 2503 | 0.030 |
Why?
|
Tetrazoles | 1 | 2000 | 905 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2009 | 8512 | 0.030 |
Why?
|
Human papillomavirus 16 | 1 | 2016 | 265 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2011 | 1765 | 0.030 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2001 | 800 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2010 | 3610 | 0.030 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2000 | 1031 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11713 | 0.030 |
Why?
|
Insulin | 1 | 2007 | 6596 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2014 | 280 | 0.030 |
Why?
|
Comorbidity | 1 | 2007 | 10553 | 0.030 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2013 | 102 | 0.030 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2013 | 143 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2009 | 8950 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2505 | 0.030 |
Why?
|
RNA, Messenger | 1 | 2007 | 12762 | 0.020 |
Why?
|
Face | 1 | 1998 | 1017 | 0.020 |
Why?
|
MART-1 Antigen | 1 | 2011 | 65 | 0.020 |
Why?
|
DNA, Protozoan | 1 | 2012 | 228 | 0.020 |
Why?
|
HLA-A2 Antigen | 1 | 2011 | 211 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2000 | 2061 | 0.020 |
Why?
|
Drug Administration Schedule | 2 | 2014 | 4899 | 0.020 |
Why?
|
Laser Therapy | 1 | 1998 | 1089 | 0.020 |
Why?
|
Antigens, Protozoan | 1 | 2013 | 316 | 0.020 |
Why?
|
Interleukin-15 | 1 | 2011 | 183 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2007 | 16932 | 0.020 |
Why?
|
France | 1 | 2011 | 511 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 14661 | 0.020 |
Why?
|
Treatment Outcome | 6 | 2014 | 64981 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2647 | 0.020 |
Why?
|
Chronic Disease | 2 | 2015 | 9288 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2011 | 631 | 0.020 |
Why?
|
Adoptive Transfer | 1 | 2011 | 822 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1088 | 0.020 |
Why?
|
Chymases | 1 | 2007 | 73 | 0.020 |
Why?
|
Neoplasm Seeding | 1 | 2008 | 84 | 0.020 |
Why?
|
Cromolyn Sodium | 1 | 2007 | 77 | 0.020 |
Why?
|
Antigen-Presenting Cells | 1 | 2011 | 967 | 0.020 |
Why?
|
Neoplasms, Unknown Primary | 1 | 2008 | 102 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2010 | 6831 | 0.020 |
Why?
|
Immunity, Humoral | 1 | 2011 | 604 | 0.020 |
Why?
|
Genetic Testing | 1 | 2020 | 3531 | 0.020 |
Why?
|
Brain Neoplasms | 1 | 2008 | 8985 | 0.020 |
Why?
|
Tryptases | 1 | 2007 | 176 | 0.020 |
Why?
|
Arm | 1 | 2009 | 583 | 0.020 |
Why?
|
Nasal Mucosa | 1 | 2009 | 412 | 0.020 |
Why?
|
Stem Cell Niche | 1 | 2009 | 346 | 0.020 |
Why?
|
Keratins | 1 | 2007 | 497 | 0.020 |
Why?
|
Nose | 1 | 2009 | 519 | 0.020 |
Why?
|
Specimen Handling | 1 | 2010 | 707 | 0.020 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2009 | 321 | 0.020 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2007 | 259 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12531 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 13627 | 0.020 |
Why?
|
Mice, SCID | 1 | 2009 | 2627 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 2008 | 983 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2013 | 4108 | 0.010 |
Why?
|
Phylogeny | 1 | 2012 | 2775 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2011 | 1889 | 0.010 |
Why?
|
Child, Preschool | 3 | 2013 | 42056 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2640 | 0.010 |
Why?
|
Embryonic Stem Cells | 1 | 2009 | 1262 | 0.010 |
Why?
|
Benzamides | 1 | 2008 | 1369 | 0.010 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2009 | 1348 | 0.010 |
Why?
|
Immune Tolerance | 1 | 2011 | 2299 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10826 | 0.010 |
Why?
|
Cell Differentiation | 2 | 2010 | 11481 | 0.010 |
Why?
|
Central Nervous System | 1 | 2008 | 1334 | 0.010 |
Why?
|
Mucous Membrane | 1 | 2004 | 657 | 0.010 |
Why?
|
Up-Regulation | 1 | 2010 | 4122 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 29957 | 0.010 |
Why?
|
Mast Cells | 1 | 2007 | 1390 | 0.010 |
Why?
|
Phenotype | 2 | 2011 | 16548 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2011 | 2924 | 0.010 |
Why?
|
Research Design | 2 | 2010 | 6180 | 0.010 |
Why?
|
Time Factors | 2 | 2013 | 40139 | 0.010 |
Why?
|
Captopril | 1 | 2000 | 265 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2005 | 1115 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2000 | 11890 | 0.010 |
Why?
|
Cell Movement | 1 | 2011 | 5206 | 0.010 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 4353 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2018 | 15790 | 0.010 |
Why?
|
Radiosurgery | 1 | 2008 | 1343 | 0.010 |
Why?
|
Heart | 1 | 2012 | 4393 | 0.010 |
Why?
|
Child | 3 | 2013 | 79799 | 0.010 |
Why?
|
Disease Progression | 1 | 2015 | 13505 | 0.010 |
Why?
|
Angiotensin II | 1 | 2000 | 849 | 0.010 |
Why?
|
Sample Size | 1 | 2000 | 840 | 0.010 |
Why?
|
Radiography | 1 | 2008 | 6965 | 0.010 |
Why?
|
Rhytidoplasty | 1 | 1998 | 68 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2004 | 1266 | 0.010 |
Why?
|
Genetic Variation | 1 | 2012 | 6552 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8552 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 25941 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9497 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2000 | 1722 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2008 | 4167 | 0.010 |
Why?
|
Epithelial Cells | 1 | 2007 | 3663 | 0.010 |
Why?
|
Survival Rate | 1 | 2009 | 12810 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 22052 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3149 | 0.010 |
Why?
|
Prospective Studies | 2 | 2015 | 54306 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15686 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2009 | 18955 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2000 | 1523 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2007 | 3454 | 0.010 |
Why?
|
Carcinoma | 1 | 2004 | 2331 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2000 | 6498 | 0.010 |
Why?
|
Transcription Factors | 1 | 2009 | 12102 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 41337 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 3725 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2007 | 6316 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13982 | 0.010 |
Why?
|
Infant | 1 | 2012 | 36053 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2005 | 10442 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15760 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2009 | 26179 | 0.010 |
Why?
|
Patient Selection | 1 | 2000 | 4279 | 0.000 |
Why?
|
Odds Ratio | 1 | 2000 | 9716 | 0.000 |
Why?
|
Follow-Up Studies | 1 | 2009 | 39262 | 0.000 |
Why?
|
Pregnancy | 1 | 2009 | 29746 | 0.000 |
Why?
|
Double-Blind Method | 1 | 2000 | 12427 | 0.000 |
Why?
|
Retrospective Studies | 1 | 2013 | 80345 | 0.000 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2000 | 10343 | 0.000 |
Why?
|
Mice | 1 | 2009 | 81209 | 0.000 |
Why?
|
Animals | 1 | 2009 | 167960 | 0.000 |
Why?
|
Postoperative Complications | 1 | 1998 | 15679 | 0.000 |
Why?
|